


SUPPLEMENTARY FIGURES




Supplementary Figure 1. The candidates of (A) IncRNAs (MIR31HG, SNHG5, PCA3) and (B) miRNAs (miR-214, miR-361, miR-575) were selected for experimental validation.



Supplementary Figure 2. The effects of knockdown of lncRNAs candidates (A) MIR31HG, (B) SNHG5 and (C) PCA3 on proliferation of RA-FLS. Data represent means \pm SEM; *p < 0.05, as determined by the Student's t test.




Supplementary Figure 3. The knockdown efficiency of MIR31HG siRNAs in RA-FLS.




Supplementary Figure 4. The KEGG pathway analysis of miR-214 overexpression RA-FLS.


Correlation analysis of MIR31HG and miR-214 in RA-FLS

Correlation analysis of PTEN and miR-214 in RA-FLS







Supplementary Figure 5. The correlation coefficient between MIR31HG and miR-214 or PTEN in RA-FLS.



Supplementary Figure 6. The validation of the inhibitory effect of LY294002 on AKT pathway in RA-FLS.



Supplementary Figure 7. The expression of MIR31HG in IL-6 KD RA-FLS.



Supplementary Figure 8. The graphic abstract of the current manuscript.

Gene ID	Gene Symbol	Туре	log2 (B3/B1)	FDR (B3 / B1)					
BGIG9606_55819	9'BGIG9606_55819'	IncRNA	7.0112272		Gene ID	Gene Symbo	l Type	log2 (B3 / B1)	FDR (B3 / B1)
	'MIR31HG' FARHGAP19-SLIT1'	IncRNA IncRNA	5.7004397 5.5235619		hsa-miR-9-	-5p	miRNA	-13.621136	6 7.87E-44
					hsa-miR-13	38-2-3p	miRNA	-12.036174	1.42E-14
BGIG9606_46824	1'BGIG9606_46824'	IncRNA	4.9541963	1 6.51E-05	hsa-miR-3		miRNA	-12.036174	1.43E-14
BGIG9606_58794	1'BGIG9606_58794'	IncRNA	4.4262647	5 1.05E-04	hsa-miR-1		miRNA	-11.929258	
BGIG9606_5180	9'BGIG9606_51809'	IncRNA	4.16992	5 3.37E-08	hsa-miR-5	75-5p	miRNA	-11.550747	7 1.65E-10
			4 0 0 0 7 4 7 0 4	9.59E-04	hsa-miR-6	64b-3p	miRNA	-11.287712	2 8.12E-09
-	L'BGIG9606_44551'	IncRNA	4.0297473		hsa-miR-2	14-5p	miRNA	-11.228819	9 1.76E-08
	LOC105378345'	IncRNA		4 3.22E-04	hsa-miR-12	225-5p	miRNA	-11.167418	3.82E-08
BGIG9606_59237	7'BGIG9606_59237'	IncRNA	3.8413022	5 4.48E-06	hsa-miR-10	06b-5p	miRNA	-11.103288	3 1.77E-08
	LOC105376244	IncRNA	3.8073549		hsa-miR-22	. 278	miRNA	-11.036174	1.76E-07
107987330		IncRNA	3.7004397		hsa-miR-6	770-5p	miRNA	-10.965784	4 3.73E-07
-	7'BGIG9606_50097'	IncRNA	3.584962		hsa-miR-36		miRNA	-10.891784	4 8.17E-07
	GATA3-AS1	IncRNA	3.3219280		hsa-miR-4		miRNA	-10.813781	
	C1QTNF3-AMACR	IncRNA	3.16992		hsa-miR-4		miRNA	-10.813781	
BGIG9606_45073	3'BGIG9606_45073'	IncRNA	3.0297473	4 6.32E-05	hsa-miR-14		miRNA	-10.550747	
BGIG9606_47247	7'BGIG9606_47247'	IncRNA		3 2.12E-09	hsa-miR-4		miRNA	-10.550747	
105376373	'LOC105376373'	IncRNA	2.6374299	2 2.36E-04					
BGIG9606 4063	L'BGIG9606 40631'	IncRNA	2.584962	5 7.08E-04	hsa-miR-2		miRNA	-10.550747	
20.0000_4000.					hsa-miR-3		miRNA	-10.451211	
BGIG9606_50404	1'BGIG9606_50404'	IncRNA	2.5025003	4 6.09E-04	hsa-miR-2	16a-5p	miRNA	-10.451211	L 3.80E-05

Supplementary Figure 9. Top 20 up-regulated IncRNAs and down-regulated miRNAs in tocilizumab-treated RA-FLS.